We have reinvestigated a classification of clinical heterogeneity among cystic fibrosis (CF) patients that we previously reported and investigated the possible relationship of the identified CF subgroups to haplotypes around the CF gene and to HLA-DR haplotypes. Age-corrected values for sweat electrolytes, rate of progression of lung disease as assessed by Brasfield chest x-ray scores, and severity of pancreatic insufficiency as assessed by daily supplemented enzyme dosage were obtained for 55, 59, and 59 patients, respectively. XV-2c and KM19 RFLPs were determined by hybridization to TaqI and PstI digests of human genomic DNA, respectively, and analysis of mutations by PCR amplification followed by allele-specific oligo-deoxynucleotide hybridization was performed for 29 patients. HLA-DR restriction fragment length polymorphisms (RFLPs) were determined by hybridization of cDNA p l and genomic DQol probes to TaqI digests of human genomic DNA. The results show that the previous subdivision on the basis of age-corrected levels of sweat electrolytes, as well as measures of severity of lung disease and pancreatic disease, is valid. In addition, the C and D haplotypes are associated with lower agecorrected sweat sodium level. No significant relationship between C F haplotypes and the other two disease variables or between HLA-DR haplotypes and any of the clinical variables was found.
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INTRODUCTION
Cystic fibrosis (CF) is the most common autosomal recessive disorder in Caucasians, affecting about one in 2,500 live births, with a carrier frequency of one in 25. The basic defect in CF is probably a genetic alteration in the control of chloride transport [Quinton and Bigman, 1983; Welsh and Liedtke, 19881 . The CF gene was at first mapped to chromosome 7 band q21-31 by linkage to multiple DNA markers Scambler et al., 1988; Wainwright et al., 1985; White et al., 19851 and recently has been cloned and partially characterized Riordan et al., 1989; Kerem et al., 1989~1 , with results suggesting that there is a probable defect in chloride transport. The presenting clinical symptoms of the disease are related mainly to chronic obstructive pulmonary involvement and malfunction of exocrine glands, leading to pancreatic enzyme insufficiency and elevation of sodium and chloride ions in sweat [Wood et al., 19761 . The considerable heterogeneity of clinical manifestations of CF is well documented. This phenomenon might reflect genetic heterogeneity of the disorder; e.g., differences among patients for features such as pancreatic function [Kerem et al., 1989al and meconium ileus [Kerem et al., 198913; Mornet et al., 1988, 19891 seem to be genetically determined. Also the distribution of haplotypes recognized by various molecular probes varies in different populations studied [Cutting et al., 1989; Devoto et al., 1989; Estivill et al., 1987a; Stern et al., 19761 , which also suggests genetic heterogeneity.
In a previous study from this laboratory, different combinations of primary clinical variables were used for subgrouping individuals affected with CF [Sing et al., 19821 . Four distinct subgroups (clusters) of individuals who varied in their laboratory values and clinical course of the disease were identified. This heterogeneity was based on three age corrected variables: sweat sodium level, pancreatic enzyme dosage, and severity of lung disease as judged by chest x-ray scores. It was shown that the information contributed by the sweat level to the clinical heterogeneity of CF patients separated clusters 1 and 2 from clusters 3 and 4 and was independent of the relationship between pancreatic damage and pulmonary function (which separated clusters 1 and 3 from clusters 2 and 4).
In the present study, the same set of clinical variables was used on a set of new patients to reappraise the original separation criteria and to search for correlations of clinical status of CF patients with four haplotypes recognized by probes XV-2c and KM19, which show significant linkage disequilibrium with the CF mutation IEstivill et al., 1987a . Because of the high incidence of diabetes (which has known HLA associations) in patients with CF [Knowles and Fernald, 1988; Rodman et al., 19861 , variable reports of a nonrandom distribution of HLA-specificities in CF patients [Kaiser et al., 1977; Hennequet et al., 1978; Herrod et al., 1979; Polymenidis et al., 19731 , and the suggestion of a role of autoimmunity in this disorder [Geffner et al., 1988; Wilkin et al., 19871 , we also screened part of our study group for HLA-Dr haplotypes [Cox et al., 19881 .
MATERIALS AND METHODS
A sample of 59 individuals of Caucasian origin affected with CF was studied. Forty-two were patients at the Mott Children's Hospital of the University of Michigan in Ann Arbor; 17 were from Wyler Children's Hospital, The University of Chicago, and Children's Memorial Hospital, Northwestern University of Chicago. Clinical data were collected by physicians in CF clinics. Sweat sodium levels were available for 55 individuals. Only levels higher than 70 mEq/L were considered to support a CF diagnosis. Pulmonary involvement was measured by chest x-ray severity score using the Brasfield scoring system. However, pulmonary damage was classified as one of four discrete classes ranging from 1 (the least severe, Brasfield score 19-25) to 4 (the most severe, Brasfield score 1-6). The Brasfield score was available for 59 individuals. GI tract involvement was quantitated in terms of the dosage of pancreatic enzyme supplementation. The standard enzyme dose was expressed in terms of equivalent number of Pancrease capsules per day. The relative medication strength based on lipase content was as follows: Pancrease 4, Cotazym and Cotazym S 5, Creon 8, and Zymase 12. The equivalent Pancrease dose was arrived a t by the equation: Pancrease dose = (medication strength x number of capsules a day) I 4. Enzyme dosage was available in 59 cases.
The deviation of an individual's age a t exam from the average of all exam ages for those who share this grade of pulmonary involvement was taken as an age-corrected measure of pulmonary severity. Individuals with positive deviations, regardless of their severity rating for the pulmonary variable, are assumed to be experiencing a less severe course of the disease than those who deviate negatively. Sweat sodium levels were adjusted by linear regression to average age of diagnosis. Pancreatic enzyme dosage was also adjusted by linear regression for age a t current dose. Age-corrected measures of "severity" for all three variables were then used in all analyses, rather than contrasting the severity rating directly (since severity is so age dependent). To compare principal components of the old and new study, two approaches were used. The first was the angular comparison of eigenvectors of principal components from both studies. In the second approach, new principal component scores, based on the previous study, were created by including new data into functions L1, L2, and L3 of Sing et al. [19821. The bivariate scatter of L2 and L3 was plotted and cutpoints from the previous study were used to check the clustering within the new sample of CF individuals.
For restriction fragment length polymorphisms (RFLP) analyses, human genomic DNA was isolated from a 5-30 ml sample of whole blood according to the method of Kunkel et al. [19771 with a slight modification. Routinely, 5 pg of DNA was digested with restriction enzyme according to manufacturer's protocols, electrophoresed through 0.9% agarose in tris-borate buffer, and transferred to Hybond-N membrane (Amersham) in 10 x SSC. The filters were hybridized in 1 M NaCl,l% SDS, 10% dextran sulphate, overnight at 65°C. Molecular probes were labeled by oligolabelling method [Feinberg and Vogelstein, 19841 . Filters were washed to final stringency of 1 x SSC a t 65°C and exposed to Kodak XAR film at -70°C with intensifying screens (Dupont Cronex Lightening-Plus). Molecular probes XV-2c and KM19 [Estivill et al., 1987a , recognizing RFLPs within TuqI and PstI digests, respectively, were used. These probes, obtained from Dr. Robert Williamson, were used to determine haplotypes for family counseling, and subsequently the data were used for this study. Haplotypes were named according to a published nomenclature [Beaudet et al., 19881. For HLA-DR typing on DNA, a cDNA p l probe [Long et al., 19831 and a genomic DQa probe [Trowsdale et al., 19831 , obtained from Dr. Richard Spielman, were used. Filters with TuqI digests of CF families' DNA samples served for the detection of band patterns specific for 18 different DR antigen types and their combinations [Cox et al., 19883 . Following hybridization, the filters were washed to a final stringency of 0.1 x SSC a t 65°C. In cases in which the pattern shared by antigens DR7 andlor DRw9-which are indistinguishable with probes DRpl and DQa in Tug1 digests, were detected-the haplotypes were all arbitrarily classified as DR7. This is justified by a very low frequency of DRw9 in Caucasians [Cox et al., 19881 . Complete DR antigen type data were available for 33 CF patients.
In order to detect the A F508 mutation, DNA was amplified using the polymerase chain reaction (PCR); 1 pM each of primers C16B and C16D [Kerem et al, 1989c , which flank the region containing the mutation, was used with 1 pg genomic DNA and 2.5 units Tuq polymerase in a total volume of 100 p l . Annealing conditions were 45 seconds a t 62"C, extension was 2 minutes a t 72"C, and denaturation was 1 minute a t 94°C for a total of 30 cycles. Then 5 pl of amplified product were denatured in 0.4N NaOH, added to 0.2 x SSC, and dot-blotted to nylon membranes. The A F508 mutation was detected using sequence specific oligonucleotides (SSOs) for the mutated (oligo-AF) and the normal sequence (Oligo-N) [Kerem et al., 1989~1 . SSOs were end-labelled with gamma-(32P)-ATP and hybridized to filter-bound DNA for 12 hours at 42°C in 0.5M NaC1, 50 mM NaPO,, 1% SDS, 5X Denhardts, and 200 kgiml salmon sperm DNA. Membranes were washed twice at room temperature for 30 minutes in 5 x SSC and 1% SDS and once at 65°C for 30 minutes each in 2 x SSC and 1% SDS. Hybridization was visualized by an autoradiograph.
RESULTS
In order to check the effect of particular XV-2clKM19 haplotypes on the three clinical variables studied, the percent distribution of haplotypes A, B, C, D, and combined haplotypes A + B, A + C, B + D, C + D (not shown) in negative and positive deviation groups has been calculated for the group of 59 patients. An analysis of variance using average deviation in sweat sodium levels, average age deviation from x-ray age class, and average deviation in pancreatic enzyme dose was performed. The values for heterozygous individuals were assigned 5050 to each allele. The results are shown in Tables 1-111. The difference in sweat sodium levels for a group of patients with combined haplotypes A + B vs. a group with combined haplotypes C + D is significant at P < .05 (Table I , analysis of variance). None of the differences in x-ray severity (Table 11 ) nor pancreatic sufficiency (Table 111 ) are statistically significant.
After this analysis was completed, the CF gene was cloned and the AF508 mutation was found to be the most common mutation, explaining 75% of CF mutations [Kerems et al., 1989~1 . The AF508 mutation is most commonly associated with the B haplotype and the B haplotype preferentially carries this mutation (although not in Ashkenazi Jewish populations). In order to see whether or not the B haplotypes of our patients predominately carried the AF508 mutation, PCR amplification and allele-specific oligodeoxynucleotide hybridization was performed on the 29 patients for whom DNA samples were still available. As seen in Table IV , the majority of BB homozygotes were homozygous for AF508, and 76.8% of B haplotypes were associated with the AF508 mutation, whereas the AF508 mutation was associated with other haplotypes only 37.5% of the time in our patient population. (We have assumed that the AF508 mutation was associated with the B haplotype in B heterozygous, AF508 heterozygous individuals.)
A subgroup of 33 individuals (all from the University of Michigan) was HLA-DR typed. An example of a Southern blot with several HLA-DR types patterns is shown in Figure 1 . Eleven different HLA-DR haplotypes were recognized among these individuals, and the distribution of all of them between clusters 1 + 2 and 3 + 4, constructed according to Sing et al. [1982] , was evaluated (Table V) . The distribution of HLA-DR types in the sample studied (66 haplotypes) is not different from a random distribution among the cluster subgroup. Table   VI presents the same analysis as in Table V , but the distribution of HLA-DRw6 (the only candidate for participation in heterogeneity as shown in Table V ) was run against all other types pooled together. These differences also are not statistically significant. We have compared principal components analyses of the group of individuals studied currently with the group of individuals described before by Sing et al.119821 The third of these orthogonal functions (L3) is a gen- The filter was subsequently probed with DQu probe to discriminate between specificities DR3 and DRw6 (lanes 5 and 6).
Of the degree Of
Of the three; the first and second are functions that contrast sweat sodium level with enzyme dose and x-ray age (L3), and x-ray age with sweat and enzyme dose values (L2). Angular comparisons of these eigenvectors with those previously published [Sing et al., 19821 are given in Table  VII . Angles near 20 or less indicate a close relationship between eigenvectors [Pimentel, 19791 . This comparison shows a close relationship between eigenvectors of component 3 from this study to component 1 of the pre- vious study and of component 1 of this study to component 3 of Sing et al. [1982] . When the group of 17 individuals diagnosed in other medical centers (Chicago) was included in this analysis, the orthogonal functions accounting for variability represented by the three analyzed variables were as following: L1 = 0.67 (sweat) -0.73 (dose) + 0.12 (x-ray age) L2 = -0.42 (sweat) -0.25 (dose) + 0.87 (x-ray age) L3 = 0.61 (sweat) + 0.64 (dose) + 0.47 (x-ray age)
Functions L1, L2, and L3 account for 36%, 34%, and 29%, respectively, of the total variability represented by the three variables. In angular comparisons of eigenvectors with the previous results of Sing et al. [1982] , only component 3 of pooled data shows a close relationship to the previous component 1 (Table VIII) .
DISCUSSION
There have been many reports on genetic heterogeneity in CF. Several studies of allelic association with DNA markers have shown that the degree of pancreatic involvement (pancreatic sufficiency vs. pancreatic insufficiency) is genetically determined and is associated with different mutant alleles [Devoto et al., 1989; Kerem et al., 1989a; Gasparini et al., 19901 . It has been shown also that American black CF patients, having milder lung disease and more severe GI tract complications [Stern et al., 19761 , have a haplotype distribution that is different from Caucasian CF patients [Cutting et al., 19893 . These results are in agreement with the general assumption that different clinical symptoms in CF could be determined by different mutant CF alleles. Extended haplotype data based on DNA markers closely linked to the putative disease gene locus [Kerem et al., 1989~1 shows that the most common haplotype correlates well with the AF508,3-bp deletion (present in approximately 75% of CF cases) and with the occurrence of pancreatic insufficiency. The remainder of CF mutant gene pool consists of multiple, different haplotypes which may each be associated with different mutations, and a minor fraction of mutant alleles (approximately 8%) may be related to better pancreatic function in a group of patients who are pancreatic sufficient. Data have also been reported on different allelic frequencies in CF families with and without meconium ileus [Mornet et al., 1988, 19891 , but they were not confirmed by other authors [Kerem et al., 1989a . When black and Caucasian groups of CF patients were screened separately, the presence of particular haplotypes was not found to be significantly associated with more severe lung disease [Cutting et al., 19891. In this study a sample of 59 CF patients was studied. Frequencies of haplotypes A, B, C, and D recognized by probes XV-2c and KM19 account for 12.7%, 72.9%,3.4%, and 11%, respectively, which is in good agreement with data reported by others for Caucasian populations [Beaudet et al., 1988; Estivill et al., 1987a, 198713; Mornet et al., 1988; Vidaud et al., 19891 . In our data, the B haplotype is not associated with either a more or less severe course of the disease measured by the three clinical variables used. The only statistically significant differences between haplotypes were found in sweat sodium levels a t the age of diagnosis: individuals with C 'Sing et al. [19821. * Indicates close relationship.
and/or D haplotype(s) had a significantly lower sodium concentration (Table I) than individuals with haplotype(s) A and/or B. Since most of the patients were B haplotype, and most of the B haplotypes studied carried the AF508 mutation, this suggests a correlation of higher age-corrected sweat electrolyte levels with this common mutation. Although not statistically significant, the C haplotype tends to associate with lower pancreatic enzyme dosage corrected for age (Table 111) . No significant differences were seen in the distribution of haplotypes between patients with less and more severe lung disease (Table 111 , which confirms the data of others [Cutting et al., 19891. There have been several attempts previously to check if the CF mutation segregates with specific HLA antigen types [Hennequet et al., 1978; Herrod et al., 1979; Kaiser et al., 1977; Polymenidis et al., 19731 . The general conclusion has been negative as far as class I HLA antigens are concerned. One report showed a statistically significant association of CF with HLA-B18 [Kaiser et al., 19771 . The prevalence of diabetes mellitus in patients with CF ranges from 8% to 15% [Knowles et al., 19881 . Clinical characteristics of diabetes in CF patients are typical of neither classic type I nor type I1 diabetes mellitus. The abnormal insulin secretion in CF patients is probably caused by destruction of pancreatic islets andior effects of scarification on islet cell secretion or paracrine function. Nevertheless, the high incidence of diabetes in CF raises a question of the phenomena of autoimmunity which are involved in this disease and, therefore, the involvement of class I1 HLA antigens in CF. We have screened (at the DNA level) part of our group of patients with regard to HLA-DR, DQ types. In the group of 33 patients, no statistically significant prevalence of particular types was shown (Table V) . However, nearly one fifth of patients screened have the HLA-DRw6 allele, which is present in the three most common haplotypes characteristic for insulin-dependent diabetes mellitus (IDDM) [Tuomilehto-Wolf et al., 19891 . The negative results of studies on circulating antibodies to islet cells or to insulin [Geffner et al., 1988; Wilkin et al., 19871 in CF patients point away from a role of autoimmune factors in the pathogenesis of diabetes in cystic fibrosis. The distribution of all class I1 HLA alleles in the cluster groups (Table V) and the distribution of HLA-DRw6 vs. all other types in these cluster groups (Table VI) has not shown that HLA-DR, DQ types contribute significantly to phenotypic heterogeneity in CF. The lack of statistical significance for these results may be due to the small size of the sample studied and the marked polymorphism of HLA-DR, DQ antigens.
A previous study from this laboratory [Sing et al., 19821 showed that it was possible to group CF patients into four significantly different subgroups using a combination of three clinical variables: degree of pulmonary involvement, sweat sodium level, and pancreatic enzyme dosage. We have again found that age-corrected variations in the concentration of electrolytes in sweat is an important variable for studies of clinical heterogeneity in CF. Indeed, it is the only variable for which we have found a significant haplotype association. When a currently studied group of patients was divided into four clusters using the same set of clinical variables and the same statistical procedures and mathematical criteria of subgrouping, the distribution of XV-2clKM19 haplotypes within clusters was random and statistically nonsignificant (not shown). It is worth mentioning that the current population was smaller than the previous one (59 vs. 104 individuals), which may well have affected the final result of the analysis. Also, individuals from this study obviously were not the same as those studied previously, although they were from almost identical geographic and ethnic backgrounds. On the other hand, the principal components which provide a general measure of the degree of involvement of the three clinical variables in heterogeneity were closely related in both studies (Table VIII) . When 42 Michigan patients were used for analysis, the similarity between principal components was much higher (Table VII) than when combined data of Michigan and Illinois patients were used (Table VIII) . This may be due to subjective differences in the evaluation of clinical status of patients within both groups by their physicians (especially evaluation of chest x-ray scores) or due to real genetic differences between these two groups.
In our study, the XV-2clKM19 B haplotype (strongly associated with the AF508 mutation in our material) appears to be associated with higher levels of sweat electrolytes corrected for age of diagnosis. It is possible that this finding is relevant to the presumed heterozygote advantage of the AF508 mutation; its frequency in northern European populations is too great to be maintained without a selective advantage. It has been argued that heterozygotes for the CF gene may have lower intestinal losses of electrolytes during enteropathogen-induced diarrhea [Bijman et al., 19881 . Quantitative decreases in heterozygote sweat secretion in response to (3-adrenergic stimulation are compatible with this hypothesis. Since "summer sickness" (gastroenteritis) of small infants led to high infant mortality before fluidielectrolyte therapy was available, a small differential in survival due to the presence of absence of the AF508 mutation could have led to the high carrier frequency.
